Brian T. Hill MD, PhD
Disclosures
Hill reports research funding from and/or consulting roles with AstraZeneca, BeOne Medicines, Bristol Myers Squibb, Genentech and Gilead Sciences/Kite Pharma.
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
There are new agents that are actually now approved and in late-stage clinical development for patients with relapsed or refractory mantle cell lymphoma. Now, it's been known for some period of time that, BCL-2 inhibition can be an effective treatment strategy in mantle cell lymphoma. And in fact, there have been randomized studies that showed that addition of the BCL-2 inhibitor venetoclax (Venclexta; AbbVie, Genentech) to, for instance, ibrutinib (Imbruvica; Johnson & Johnson, Pharmacyclics), showed significantly improved progression-free survival and response rate compared to ibrutinib alone.
